Stoppen Met Antidepressiva

Preview:

DESCRIPTION

Lezing UPPER slotbijeenkomst 3 juli 2009

Citation preview

Department of Pharmaceutical Sciences

Antidepressivagebruikers stoppen er mee

3 Juli 2009Dr. E.R. Heerdink

Department of Pharmaceutical Sciences

Rob Heerdink

Pharmacoepidemiology & PharmacotherapyUtrecht Institute for Pharmaceutical SciencesUniversiteit UtrechtThe Netherlands

www.pharm.uu.nl/epithera

Department of Pharmaceutical Sciences

Depression in The Netherlands

Year prevalence depression: – 6% of the population – 900.000 patients per year

Average episode 6 months– In 70-80% relapse– 15-20% is chronically depressed

Depression related costs:– 660 Mil € direct– 3.8 Bil € indirect per year

Trimbos Instituut 2006; Andrade L et al , Bull World Health Organ 78:413-426

Department of Pharmaceutical Sciences

0,0

1,0

2,0

3,0

4,0

5,0

6,0

7,0

8,0

1992 1993 1994 1995 1996 1997 1998 1999 2000 2001

Prevalence SSRI

Incidence SSRI

Prevalence TCAIncidence TCA

Indexed prevalence and incidence per year of antidepressant use during 1992-2001 (1992=1).

Meijer et al. Eur J Clin Pharmacol (2004) 60: 57–61

Department of Pharmaceutical Sciences

Are Subjects in Pharmacological Treatment Trials of Depression Representative of Patients in Routine Clinical Practice?Mark Zimmerman, M.D., Jill I. Mattia, Ph.D., and Michael A. Posternak, M.D

Am J Psychiatry 159:469-473, March 2002

‘Of 346 patients with ‘major depression’ only 14% are eligible according to inclusioncriteria for trials with antidepressants’

Department of Pharmaceutical Sciences

Depression treatment guidelines

1st episode: At least 6 months continued use following disappearance of symptoms

relapse or chronic:At least 1 year continued use following remission

937.020

Gip databank 2007

937.020

702.765

Meijer et al 2004

234.255Chronic users

937.020

702.765

Van Geffen et al 2008

30.200primary defaulting

+

937.020

702.765

541.130

Van Geffen et al 2008

161.636only 1 prescription

937.020

702.765

541.130

189.750

Van Geffen et al 2008

175.690< 6 months

175.690>12 months

937.020

702.765

541.130

189.750

68.310Van Geffen et al 2008

121.440no tapering

937.020

68.310

Department of Pharmaceutical Sciences

Department of Pharmaceutical Sciences

937.020

702.765

541.130

541.130 189.750

68.310

68.310189.750

541.130

702.765

541.130

541.130 189.750

68.310 937.020

702.765 702.765

702.765

Department of Pharmaceutical Sciences

937.020

702.765

541.130

541.130 189.750

68.310

68.310189.750

541.130

702.765

541.130

541.130 189.750

68.310 937.020

702.765 702.765

702.765

Department of Pharmaceutical Sciences

Department of Pharmaceutical Sciences

Department of Pharmaceutical Sciences

Department of Pharmaceutical Sciences

Apotheker

=

Geneesmiddelen informatie specialist

Department of Pharmaceutical Sciences

Initiation phase

Goal:

Estimate incidence of:

primary defaulting;

filling only one prescription

Identification of patient characteristics

Department of Pharmaceutical Sciences

Initiation phase

965 patients with a first prescription for a treatment with an antidepressant:

4.2% (42) do not pick up the antidepressant

23.7% (229) picks up only 1 prescription

Department of Pharmaceutical Sciences

Characteristics of non-starters

OR* 95% CI

Non-specific indication 2.67 1.82-3.91

Niet-western immigrants 4.80 2.05-11.3

>60 years of age 1.81 1.18-2.78

Precollege education level 1.40 0.83-2.36

Poor/moderate self-rated health 1.11 0.76-1.63

Paroxetine 0.78 0.53-1.13

Van Geffen et al Br J Gen Pract (feb 2009)

Reasons for not starting therapy

57 patients with a single prescription

17 non-starters (29,8%)

Fear of side effects (8)

Aversion towards medication use (3)

Pregnancy (2)

Feeling better (2)

Fear of addiction (1)

Practical reasons (1)

40 (70,2%) stopped within 14 days

Side effect (25)

Aversion towards medication use (7)

Feeling better (6)

Medication ineffective (1)

disagree with diagnosis (1)Ann Pharmacother 2008; 42:218-25

Department of Pharmaceutical Sciences

“al dat gepraat.. Geef mij maar een pil”

Department of Pharmaceutical Sciences

Department of Pharmaceutical Sciences

Patient A (female, 34, paroxetine 1dd)

Department of Pharmaceutical Sciences

Patient B (male, 41, paroxetine 1dd)

Department of Pharmaceutical Sciences

Department of Pharmaceutical Sciences

• 46 stage apotheken gevraagd

• 37 deelnemers

• September – December 2008

• 12-15 antidepressivagebruikers per apotheek

• 46.2% response (245/530)

Department of Pharmaceutical Sciences

Female gender129 (62.9)

Age 18-30 years 25 (12.2)

31-45 years 61 (29.8)

45-60 years 87 (42.4)

>60 years 32 (15.6)

EducationLow 57 (27.8)

Middle 83 (40.5)

High 60 (29.3)

Having a partner 118 (57.6)

Employment or in school 105 (51.2)

Living with others 141 (68.8)

Department of Pharmaceutical Sciences

Type of antidepressant Paroxetine 88 (42.9)

Citalopram 48 (23.4)

Fluoxetine 24 (11.7)

Other 45 (22.0)

Reason for use Depression 154 (75.1)

Anxiety 100 (48.8)

Department of Pharmaceutical Sciences

• 71% gat in de medicatiehistorie

•27% overlap

•2% precies op tijd

Department of Pharmaceutical Sciences

MARS

•Ik vergeet mijn medicijnen in te nemen

•Ik verander de dosis

•Ik stop tijdelijk

•Ik sla een dosis over

•Ik gebruik minder dan voorgeschreven

Department of Pharmaceutical Sciences

Adherent (MARS)

All patients (n=205) 153 (74.6)

Gap days

Any (n=147) 107 (72.8)

<5% of OTT (n=40) 38 (95.0)*

5%-19.9% of OTT (n=45) 36 (80.0)*

≥20% of OTT (n=62) 33 (53.2)

Overlapping days

Any (n=53) 41 (77.4)

<5% of OTT (n=20) 18 (90.0)

5%-19.9% of OTT (n=18) 13 (72.2)

≥20% of OTT (n=15) 10 (66.7)

No overlap or gap days (n=5) 5 (100.0)

Department of Pharmaceutical Sciences

Meldt u dat uw geneesmiddelen anders gebruikt?

Geen gaten

Aan arts: 65%

Aan apotheker: 40%

Wel gaten

Aan arts: 40%

Aan apotheker: 19%

Department of Pharmaceutical Sciences

Stopping 21% (14) stop abruptly

42% (28) stop with a homemade tapering scheme

30% (20) use a tapering scheme from the GP

6% (4) use a tapering scheme from psychiatrist

Eur J Clin Pharmacol 2005; 61:303-307

Department of Pharmaceutical Sciences

Discontinuation symptoms

  patients DESS-events Gem. (SEM)

P-value 

Overall 66 7.2 (0,9)

stopping

tapering 52 5.9 (0.9) 0.006

Abrupt 14 12.0 (2.6)

Eur J Clin Pharmacol 2005; 61:303-307

Department of Pharmaceutical Sciences

Who fills the need?

pharmacist doctor patient

Department of Pharmaceutical Sciences

Department of Pharmaceutical Sciences

Department of Pharmaceutical Sciences

email: e.r.heerdink@uu.nl

slides: slideshare.net/robheerdink

twitter: @knutmo

Recommended